Disclosure Plus

BENO TNR Decides on 100억 원 Third-Party Private Placement

[Edaily Reporter Park Sun-Yeop ] BENO TNR(206400)announced on the 3rd that it has decided to conduct a third-party private placement worth 9,999,900,000 won with Acro New Technology Fund No. 241 to raise operating funds.
A total of 11,737,089 common shares will be issued. The issue price per share is 852 won, calculated by applying a 10% discount to the reference share price of 946 won.
The total number of shares outstanding prior to the capital increase is 37,510,158 common shares. The payment date is December 23, and the new shares are scheduled to be listed on January 11, 2027.
The funds raised will be used for operating expenses and other costs necessary for the company’s operations. The company plans to use 3 billion won in 2027 and 7 billion won starting in 2028.
Acro New Technology Fund No. 241, the subscriber for this rights offering, is the same party with whom the company previously entered into a share transfer agreement involving a change in the largest shareholder. BENO TNR explained that it selected the allottee by considering the investor’s intent, payment capacity, and timing in order to achieve the company’s business objectives and secure funds promptly.
All new shares issued through this rights offering are scheduled to be locked up for one year at the Korea Securities Depository.

Economy

Corporation

IT·Science

Economy

A Semiconductor Fabless Company Founded by SK Hynix’s Youngest-Ever Executive [VC Cradle]

The biggest bottleneck for AI servers is memory. As the KV cache—where large language models (LLMs) store past computations—accumulates, the required memory capacity increases exponentially. This prob…
2026-07-04 09:00:07

Corporation

Genosco, Tax Risk?… “Lecraza Is ‘Royalty Income’; Its Value Remains Unchanged”

Concerns about “tax risks” have been raised in some quarters of the financial investment, pharmaceutical, and biotech markets regarding Genosco, a subsidiary of OSCOTEC Inc.(039200)specializing in new…
2026-07-04 08:31:02

IT·Science

Celltrion Pharm Inc. Builds a Plant, AriBio Secures Investment… K-Bio in ‘Expansion Mode’ [Weekly Bio Roundup]

As July began (June 29–July 3), the pharmaceutical and biotech industries turned their attention to Celltrion Pharm Inc.’s large-scale investment in production facilities and AriBio’s successful fundr…
2026-07-04 09:01:02